To assess the cost-effectiveness of a nurse facilitated, cognitive behavioural self-management programme for patients with heart failure compared with usual care including the un-facilitated access to the same manual, from the perspective of the NHS. METHODS: Data were obtained from a pragmatic, multicentre, randomised controlled 'open' trial conducted in seven centres in the UK between 2006 and 2008. Effectiveness was estimated as Quality-Adjusted Life Years. Resource use was measured prospectively on all patients using information provided by patients in postal questionnaires, case-note review, electronic record review and interviews with patients. Unit costs were obtained from the literature and applied to the relevant resource use to estimate total costs. Multiple imputation was used to handle missing data. RESULTS: There were no substantial differences in the utility scores between treatment groups in all follow-up assessments, in the use of medication or outpatient visits and both groups report a similar frequency of contact with health care professionals. After controlling for baseline utility and using imputed dataset, treatment was associated with a reduction in QALY of 0.004 and a reduction in costs of £116.2, generating an incremental costeffectiveness ratio of £29,036 for usual care. The probability that the intervention is cost-effective for thresholds between £20,000 and £30,000 is around 60%. CONCLUSIONS: There is little evidence that the addition of the intervention had any effect on costs or outcomes. The uncertainty around both estimates of cost and effectiveness mean that it is not reasonable to make recommendations based on cost-effectiveness alone.
OBJECTIVES:
The 2012 European guideline on cardiovascular disease prevention recommends statin therapy for individuals with elevated cholesterol levels and with an intermediate risk of fatal events. However, since many individuals fall into this category, improved discrimination is needed to prevent both cardiovascular disease (CVD) and statin side-effects (e.g. myopathy) efficiently. We estimated the potential cost-effectiveness of a novel biomarker test which helps to decide which individuals with an intermediate risk should receive statins. METHODS: Prognosis of different age-and gender-specific cohorts with an intermediate risk was simulated with a literature-based Markov model to estimate the potential costs and quality-adjusted life-years (QALYs) for four strategies: treat all with statins, treat none with statins, treat according to the European guideline or use a test to select individuals for statin treatment. Costs were calculated for the Netherlands using a health care sector perspective. RESULTS: The test-first strategy was the least expensive strategy as long as a perfect test cost no more than €304 at a threshold of €20000 per QALY gained. The perfect test-first and treat-all strategy reduced the same number of events leading to comparable QALYs but the test generated lower medication and drug side-effect costs. The treat-none strategy was the least costeffective strategy. The test needs to be very accurate and inexpensive in order to be the most cost-effective strategy, since the impact of myopathy on cost-effectiveness is negligible and statin costs are low. CONCLUSIONS: A test that improves treatment decisions for individuals with an intermediate CVD risk has the potential to optimize cost-effectiveness by reducing the risk of drug side-effects and budget impact. However, given the outcomes of this 'early stage' cost-effectiveness analysis there may be limited value in developing a test with this indication. Early stage economic evaluations can assist industry in determining whether a test is worth developing. OBJECTIVES: Aortic valve replacement (AVR) is the most common heart valve operation, accounting for a conspicuous part of all valve surgery performed in the elderly. A significant subset of patients with indications for valve surgery are deemed ineligible for conventional valve replacement because of high-risk features or age. Prolonged aortic cross-clamping times (CCT) are an independent risk factor for worse outcomes. Perceval S is a new aortic valve which is implanted without need for suturing and a collapsed profile, thus allowing a significant reduction of cross-clamping times. Aim of this simulation study was to predict costs and outcomes of concomitant AVR procedures associated with this new valve in 4 European countries (Italy, France, Germany, and UK), as compared to traditional valve implants, from the cost perspective of the hospital. METHODS: A probabilistic, patient-level simulation model was fully coded in WinBugs, permitting a seamless integration of parameter estimation and outcomes prediction, which was en-tirely based on the associated CCTs, through published correlations. Unit cost were retrieved from official and literature sources for all countries. Besides the incorporated probabilistic sensitivity analysis, a series of deterministic sensitivity analyses was performed. RESULTS: The model predicts less complications with the use of the Perceval S valve, and savings (valve cost excluded) ranging from about 6,000 € (Italy) to about 6,700 £ (UK), mainly related to a reduction in surgery costs and ICU/hospital bed days. Extensive sensitivity analyses confirm the robustness of such findings. CONCLUSIONS: Reduced cross clamping times associated with the implantation of Perceval S result in relevant savings on surgical, complication managment and hospital stay costs in all analysed settings.
CV3 OUTCOMES AND COSTS OF CONCOMITANT AORTIC VALVE REPLACEMENTS ASSOCIATED WITH A NEW SUTURELESS AND COLLAPSED VALVE IN ITALY, FRANCE, GERMANY, AND THE UK
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EVALUATION OF TELEMONITORING FOR HEART FAILURE PATIENTS WITH IMPLANTABLE DEFIBRILLATORS: THE EVOLVO (EVOLUTION OF MANAGEMENT STRATEGIES OF HEART FAILURE PATIENTS WITH IMPLANTABLE DEFIBRILLATORS) STUDY
Zanaboni P 1 , Marzegalli M 2 , Landolina ME 3 , Lunati M 4 , Perego GB 5 , Guenzati G 2 , Curnis A 6 , Borghetti F 7 , Beccagutti G 7 , Borghi G 8 , OBJECTIVES: Heart failure patients with implantable defibrillators (ICD) frequently undergo in office visits, placing a great burden on health care providers. Internetbased remote device interrogation systems are being proposed in order to reduce these visits, as well as to promptly detect and notify alert conditions. METHODS: EVOLVO was a prospective, randomized, parallelmulticenter clinical trial comparing remote ICD management with the current standard of care, assessing their effectiveness and costs.Primary end-point: rate of cardiac or device related unplanned emergency department (ED) or urgent in-office visits. Secondary endpoint: all health care utilizations for HF, arrhythmias or device related events; quality of life (QoL), assessed with the Minnesota Living with Hearth Failure Questionnaire (MLHFQ), and EuroQol five Dimensions (EQ 5D). Costs were considered from National Health Services (NHS) and patients' and society point of view. RESULTS: Two hundred patients (79% males; 66Ϯ10years) implanted with ICD (92% biventricular ICD) were enrolled in five Hospitals in Italy, with a follow-up of 16 months.The rate of visits considered in primary endpoint was reduced by 36% in remote arm (75 versus 117; Incidence density: 0.59 versus 0.93 events/year; pϭ0.005). Overall, there were 1285 health care utilizations (secondary endpoint) with a difference of 23% in the rates of events (4.40 events/year in remote arm vs 5.74 events/year in standard arm).The telemonitoring implied annual cost saving per patient-year for NHS: €1962.78 for remote arm versus €2130.01 for the standard arm. Further, remote arm gained 0.065 QALYs per patient vs standard arm. From patients and society point of view, a cumulative costs per patient-year of 154 € (standard arm) versus 112 € (remote arm) was assessed. CONCLUSIONS: Remote management of chronic heart failure patients with ICD is a cost-effective solution, with clinical and economic benefits for both health care systems and patients. A large-scale adoption should be supported. 1%) , and 2 of 53 natalizumab patients (3.8%) with glatiramer acetate, 4% with natalizumab. Median times to switch ranged from 1.8 to 2.5 years. Adherence rates were high: percentage of patients achieving DMPRϾ80% ranged from 78.1% to 88.9%. Probability of drug persistence was, on average, about 80% at the end of first year of observation, being similar across different treatments. CONCLUSIONS: Patients tend to adhere quite well to prescribed DMA medication. However, a relevant number of patients receive therapy adjustment or modification in the short term period (after about two years of treatment), maybe because of lack of efficacy or adverse events occurrence, both factors discouraging or impeding continuation. DENALI shows to be an efficient instrument to assess prescription patterns of DMAs, although linkage with clinical registries would remain necessary to assess reasons of switch/drop out, and to evaluate DMAs' efficacy.
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